SLC5A2 and type 2 diabetes mellitus: It has been hypothesized that mild but persistent hyperketonemia during treatment with an SGLT2 inhibitor results in significant risk reductions in both cardiovascular and renal outcomes in individuals with type 2 diabetes [35].